January 9, 2025

Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients

CAMBRIDGE, Mass., January 9, 2025 – Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years.

Learn More
January 7, 2025

Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. – Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that Michel Dahan, President and Chief Executive Officer, will provide a corporate update and present the latest clinical study results for the company’s investigational oral therapy to prevent blindness in patients with Stargardt disease, during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.

Learn More
December 5, 2024

Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy

CAMBRIDGE, Mass., December 5, 2024 – Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of Stargardt disease (TEASE) will be presented at the 12th International FLORetina ICOOR Congress being held December 5-8 in Florence, Italy.

Learn More
November 18, 2024

Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease

CAMBRIDGE, Mass. — Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that gildeuretinol (ALK-001), an investigational oral therapy, has received Rare Pediatric Disease and Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of Stargardt disease.

Learn More